更正：抗SARS-CoV-2治疗性单克隆抗体的现状
Correction: Current status of therapeutic monoclonal antibodies against SARS-CoV-2.
作者信息
Kumar Sanjeev, Chandele Anmol, Sharma Amit
出版信息
PLoS Pathog. 2022 Nov 21;18(11):e1010983. doi: 10.1371/journal.ppat.1010983. eCollection 2022 Nov.
Abstract
[This corrects the article DOI: 10.1371/journal.ppat.1009885.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.ppat.1009885。]
相似文献
1
Correction: Current status of therapeutic monoclonal antibodies against SARS-CoV-2.更正：抗SARS-CoV-2治疗性单克隆抗体的现状
PLoS Pathog. 2022 Nov 21;18(11):e1010983. doi: 10.1371/journal.ppat.1010983. eCollection 2022 Nov.
2
Correction: A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.更正：基于水疱性口炎病毒的初免-加强疫苗接种策略可诱导产生针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的强效保护性中和抗体。
PLoS Pathog. 2022 Nov 29;18(11):e1011000. doi: 10.1371/journal.ppat.1011000. eCollection 2022 Nov.
3
Correction: Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins.更正：抗凝血酶原自身抗体在感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）后富集，并受针对SARS-CoV-2蛋白的抗体反应强度影响。
PLoS Pathog. 2022 Feb 2;18(2):e1010289. doi: 10.1371/journal.ppat.1010289. eCollection 2022 Feb.
4
Correction: Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?更正：穿山甲是2019新型冠状病毒（SARS-CoV-2）的中间宿主吗？
PLoS Pathog. 2021 Jun 9;17(6):e1009664. doi: 10.1371/journal.ppat.1009664. eCollection 2021 Jun.
5
Correction: Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.更正：人类对急性SARS-CoV-2感染的抗体反应的广度和功能
PLoS Pathog. 2021 Dec 10;17(12):e1010148. doi: 10.1371/journal.ppat.1010148. eCollection 2021 Dec.
6
Correction: The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation.更正：SARS-CoV-2基因背景在刺突突变出现及成功传播中的结构作用：以刺突A222V突变为例
PLoS Pathog. 2022 Nov 23;18(11):e1010995. doi: 10.1371/journal.ppat.1010995. eCollection 2022 Nov.
7
Correction: SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon.更正：严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抑制由非结构蛋白1、5、6、15、开放阅读框6（ORF6）和开放阅读框7b（ORF7b）介导的Ⅰ型干扰素β（IFNβ）产生，但不抑制添加的干扰素的作用。
PLoS Pathog. 2021 Dec 10;17(12):e1010146. doi: 10.1371/journal.ppat.1010146. eCollection 2021 Dec.
8
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.更正：治疗中断后潜伏的HIV平均每5 - 8天重新激活一次——对HIV缓解的影响
PLoS Pathog. 2016 Aug 25;12(8):e1005745. doi: 10.1371/journal.ppat.1005745. eCollection 2016 Aug.
9
Correction: Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19.更正：广泛定向的SARS-CoV-2特异性CD4+ T细胞反应包括在急性和已康复的COVID-19患者的膜蛋白和核蛋白中经常检测到的肽特异性。
PLoS Pathog. 2022 Jan 5;18(1):e1010220. doi: 10.1371/journal.ppat.1010220. eCollection 2022 Jan.
10
Correction: Viral burden is associated with age, vaccination, and viral variant in a population-representative study of SARS-CoV-2 that accounts for time-since-infection-related sampling bias.更正：在一项针对SARS-CoV-2的具有人群代表性的研究中，病毒载量与年龄、疫苗接种及病毒变体相关，该研究考虑了与感染时间相关的抽样偏差。
PLoS Pathog. 2023 Oct 6;19(10):e1011706. doi: 10.1371/journal.ppat.1011706. eCollection 2023 Oct.
本文引用的文献
1
Current status of therapeutic monoclonal antibodies against SARS-CoV-2.抗SARS-CoV-2治疗性单克隆抗体的现状
PLoS Pathog. 2021 Sep 3;17(9):e1009885. doi: 10.1371/journal.ppat.1009885. eCollection 2021 Sep.
Zotero 插件